ReviewBiotechnology advances2025
Myxobacteria: Versatile cell factories of novel commercial enzymes for bio-manufacturing.
Review in Biotechnology advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development of efficient genetic toolkits and heterologous chassis for bioprospecting of myxobacteria.Nature communications · 2026Article
- South African Myxococcota: an untapped resource for microbial ecolo gy and biotechnology.Applied microbiology and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Microbial cell factories for the production of high-quality commercial-grade enzymes have accelerated the development of advanced bio-manufacturing approaches, which in turn are environmentally friendly and sustainable. Myxobacteria, a term commonly used to refer to a group within the Myxococcota phylum, are of great interest for their biotechnological applications due to their ability to synthesize a wide range of natural products and lytic enzymes. These traits are essential for the development of robust expression systems. However, myxobacteria have remained an underexploited resource with industrial relevance. Nevertheless, a growing number of food and industrial enzymes have been identified, highlighting myxobacteria as suitable platforms for exploring enzymes with commercial applications, including biomass conversion. Yet, the discovered lytic enzymes are just the tip of the iceberg given their large genomes and diversity across myxobacteria taxa. Despite holding much promise, challenges in genetic engineering, slow growth, and limitations in metabolic remodeling and expression strategies have limited the construction of myxobacterial cell factories. In this review, we highlight recent advances in the discovery of new myxobacterial enzymes and biomass conversion resources, focusing on their potential applications in agriculture and industry. We describe how myxobacteria and their enzymes can be identified through bioprospecting and computational approaches and summarize current biotechnological applications and synthetic biology strategies for bio-manufacturing. Finally, we discuss the promising potential of myxobacteria as industrial cell factories and address open research questions and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.